Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 6/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9549253 | 0.90 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL14430372 | 0.87 | KDM4E (0.59) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL31597571 | 0.86 | KDM4E (0.79) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL1274261 | 0.86 | KDM4E (0.79) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL9448294 | 0.83 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL9041741 | 0.80 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL16556084 | 0.80 | KDM4E (0.61) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL10835300 | 0.80 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL7410003 | 0.80 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDGLAGAA | |
| SCHEMBL29525031 | 0.80 | ALDH1A1 (0.41) | ALDH1A1KDM4EGAAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4660185-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING AMIDES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024159288-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING AMIDES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2024-08-08 | — | — | WO | disclosed |
| US-11446298-B2 | Pyrimidine derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-09-20 | — | — | US | disclosed |
| EP-3625223-B1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-08-11 | — | — | EP | disclosed |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2020-04-09 | — | — | US | disclosed |
| EP-3625223-A1 | PYRIMIDINE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| CN-110621667-A | Pyrimidine derivatives | 爱杜西亚药品有限公司 | 2019-12-27 | — | — | CN | disclosed |
| WO-2018210992-A1 | PYRIMIDINE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| US-6503935-B1 | Treating urinary incontinence or retrograde ejaculation | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
| EP-1259491-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | Abbott Laboratories (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060802-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES, AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | ABBOTT LABORATORIES (US) | 2001-08-23 | — | — | WO | disclosed |
| EP-1102754-A1 | IMIDAZOLES AND RELATED COMPOUNDS AS ALPHA-1A AGONISTS | ABBOTT LABORATORIES (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007997-A1 | IMIDAZOLES AND RELATED COMPOUNDS AS α1A AGONISTS | ABBOTT LABORATORIES (US) | 2000-02-17 | — | — | WO | disclosed |
| US-5480873-A | ARTHRITIS | LILLY INDUSTRIES LIMITED (GB) | 1996-01-02 | — | — | US | disclosed |
| US-5288749-A | Treating central nervous system or cardiovascular disorders | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
| EP-0570091-A1 | Anthraquinone derivatives, process for their preparation and their use as medicaments | LILLY INDUSTRIES LIMITED (GB) | 1993-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | ALDH1A1 263/4885KDM4E 823/4885HPGD 2765/4885 |
| US-11446298-B2 | Pyrimidine derivatives | PTGER1, PTGER4, PTGER2 | ALDH1A1 418/4885KDM4E 1545/4885HPGD 226/4885 |
| US-20200108068-A1 | PYRIMIDINE DERIVATIVES | PTGER1, PTGER4, PTGER2 | ALDH1A1 418/4885KDM4E 1545/4885HPGD 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.